Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)
ACROSS Study Group
MetadataShow full item record
Background: This phase II study aims to evaluate the efficacy and safety of biweekly cetuximab in combination with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) as first-line treatment of metastatic wild-type KRAS colorectal cancer. Methods: Previously untreated patients with wild-type KRAS tumours received biweekly cetuximab (500 mg/m2 on day 1) plus FOLFOX-4 (oxaliplatin 85 mg/m2 on day 1, leucovorin 200 mg/m2 on days 1 and 2, and fluorouracil as a 400 mg/m2 bolus followed by a 22-hour 600 mg/m2 infusion on day 1 and 2). Treatment was continued until disease progression, onset of unacceptable toxicities, metastases surgery, or discontinuation request. The primary endpoint was ORR. Results: The intention-to-treat population included 99 patients with a median age of 64.1 years (range, 34-82). The ORR was 60.6% (95% CI, 50.3% to 70.3%). The median follow-up was 17.8 months; the median OS and PFS were 20.8 and 10.1 months, respectively. Metastases from colorectal cancer were surgically resected in 26 (26.3%) patients, with complete resection achieved in 18 (69.2%) patients. Median PFS and OS in patients undergoing metastatic resection were 12.6 and 29.5 months, respectively. The most common grade 3-4 toxicities were neutropenia (32.3%), acne-like rash (15.2%) and diarrhoea (11.1%). Conclusions: The efficacy of the biweekly combination of cetuximab with FOLFOX-4 in patients with wild-type KRAS tumours supports the administration of cetuximab in a dosing regimen more convenient for patients and healthcare providers. The activity of the biweekly administration is similar to what has been reported for the weekly regimen. Reported toxicity was also consistent with the known toxicity profile of weekly cetuximab. Trial registration: EudraCT Number 200800690916
Is part ofBMC Cancer, 2017, vol. 14, p. 865
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by (c) Fernandez-Plana et al., 2017
Showing items related by title, author, creator and subject.
Coexpression of p-IGF-1R and MMP-7 modulates panitumumab and cetuximab efficacy in RAS Wild-Type metastatic colorectal cancer patients Alonso, Vicente; Escudero, Pilar; Fernández-Martos, Carlos; Salud Salvia, Maria Antonieta; Méndez, Miguel; Gallego, Javier; Rodriguez, Jose-R.; Martín-Richard, Marta; Fernández-Plana, Julen; Manzano, Hermini; Méndez, José-Carlos; Zanui, Monserrat; Falcó, Esther; Gil-Raga, Mireia; Rojo, Federico; Cuatrecasas, Miriam; Feliu, Jaime; García-Albéniz, Xabier; Maurel, Joan (Elsevier, 2018)INTRODUCTION: The coexpression of pIGF-1R and MMP-7 (double-positive phenotype, DP) correlates with poor overall survival (OS) in KRAS wild-type (WT) (exon 2) metastatic colorectal cancer (mCRC) patients treated with ...
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer Loupakis, Fotios; Stein, Alexander; Ychou, Marc; Hermann, Frank; Salud Salvia, Maria Antonieta; Österlund, Pia (Springer, 2016)Colorectal cancer is the third most common cancer worldwide. A significant proportion of patients presents with unresectable metastatic disease or develops metachronous metastases following surgical resection of the primary ...
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer Feliu, Jaume; Safont, M. J.; Salud Salvia, Maria Antonieta; Losa, F.; García-Girón, C.; Bosch, Carlos; Escudero, P.; López, R.; Madroñal, C.; Bolaños, M.; Gil, M.; Llombart, A.; Castro-Carpeño, J.; González-Barón, M. (Nature Publishing GroupCancer Research UK, 2010)BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based ...